I already violated my rule against speculating on the outcome
of a case based on oral argument, I might as well do it again.
I have always said that EPA's endangerment finding would
survive judicial review and that conclusion seems only more likely
to prove correct following yesterday's oral argument before the
D.C. Circuit Court of Appeals.
Both the Daily Environment Report and GreenWire noted in their reporting on the
argument that the groups challenging the rule emphasized that EPA
had not considered the policy implications of making the
endangerment finding. Of
course. Precisely. That's because the Clean Air Act
itself divorces the endangerment finding from its policy
implications. If there were any doubt about that, Massachusetts to EPA would seem to
have put such questions to rest.
Judges Tatel and Sentelle both seemed to understand this
point. Judge Tatel apparently felt compelled to remind the
petitioners that the Court of Appeals is bound by Massachusetts
v. EPA. Judge Sentelle said that:
"Sometimes in reading the petitioners briefs, I got the
impression that Massachusetts had not been
To which, the petitioners said "uh-oh".
There are a lot of issues in these cases. EPA could lose
parts of some of the rules under challenge. The Tailoring Rule
in particular still seems on thin ice to me – though I
don't know what alternatives EPA really had (and all heck will
certainly break loose if the endangerment finding is affirmed but
the Tailoring Rule is overturned). Nonetheless, the
endangerment finding itself seems compelled by the plain language
of the CAA and the decision in Massachusetts v. EPA,
unless EPA's scientific conclusion is arbitrary and capricious
– and it ain't, by a long mile.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
Foley Hoag will present a 60-minute webinar on Wednesday, January 25, 2017 at 12:30 pm EST offering guidance to in-house counsel on best practices for pharmaceutical and biologics companies in selecting, vetting, and seeking approval for medication product names. The focus will be primarily on the U.S. market, although foreign strategies may be addressed as well.
25 Jan 2017, Seminar, Massachusetts, United States
Please join us on Wednesday, January 25 at the Westin Waltham Hotel for our quarterly New England M&A Forum, which brings the latest in market trends and recent legal developments to the New England M&A professionals' community.
Sellers love them, buyers hate them, but auctions are a mainstay of the M&A landscape. Our panel of experts, led by Foley Hoag partner Bill Kolb, will discuss legal, business and strategic considerations in structuring and participating in auctions from both the buy-side and the sell-side.
President-Elect Donald Trump has vowed to scrap President Obama's CPP rule, the cornerstone of Obama's environmental legacy. The rule establishes the first national standards to limit carbon pollution...
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).